Victory Capital Management Inc. Sells 36,608 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Victory Capital Management Inc. decreased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 17.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 172,879 shares of the company’s stock after selling 36,608 shares during the period. Victory Capital Management Inc.’s holdings in Krystal Biotech were worth $21,447,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its stake in Krystal Biotech by 111.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company’s stock valued at $83,000 after purchasing an additional 379 shares during the last quarter. Fox Run Management L.L.C. bought a new position in shares of Krystal Biotech during the third quarter valued at $219,000. Prime Capital Investment Advisors LLC bought a new position in shares of Krystal Biotech during the fourth quarter valued at $310,000. Graham Capital Management L.P. bought a new position in shares of Krystal Biotech during the third quarter valued at $330,000. Finally, Confluence Wealth Services Inc. raised its stake in shares of Krystal Biotech by 20.7% during the third quarter. Confluence Wealth Services Inc. now owns 2,920 shares of the company’s stock valued at $339,000 after acquiring an additional 500 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Up 0.7 %

Shares of NASDAQ KRYS opened at $158.74 on Friday. Krystal Biotech, Inc. has a twelve month low of $86.03 and a twelve month high of $189.97. The firm has a fifty day simple moving average of $168.75 and a 200 day simple moving average of $134.44. The company has a market capitalization of $4.53 billion, a PE ratio of 84.89 and a beta of 0.91.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, May 6th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.20 by ($0.17). The business had revenue of $45.25 million for the quarter, compared to analysts’ expectations of $47.37 million. During the same period in the prior year, the business posted ($1.76) earnings per share. The company’s quarterly revenue was up 452400.0% on a year-over-year basis. As a group, equities analysts expect that Krystal Biotech, Inc. will post 1.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. William Blair reaffirmed an “outperform” rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price target on shares of Krystal Biotech in a research note on Monday. Guggenheim raised their price target on shares of Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Citigroup raised their price target on shares of Krystal Biotech from $160.00 to $195.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $204.00 target price (up previously from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $171.00.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the sale, the insider now directly owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the sale, the insider now directly owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CAO Kathryn Romano sold 5,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total transaction of $829,400.00. Following the sale, the chief accounting officer now directly owns 12,936 shares of the company’s stock, valued at $2,145,823.68. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,087 shares of company stock valued at $6,210,591. Corporate insiders own 14.10% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).